• Je něco špatně v tomto záznamu ?

(E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells

A. Stefela, M. Kaspar, M. Drastik, T. Kronenberger, S. Micuda, M. Dracinsky, B. Klepetarova, E. Kudova, P. Pavek

. 2021 ; 12 (-) : 713149. [pub] 20210813

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024161

Bile acids (BAs) are key signaling steroidal molecules that regulate glucose, lipid, and energy homeostasis via interactions with the farnesoid X receptor (FXR) and G-protein bile acid receptor 1 (GPBAR1). Extensive medicinal chemistry modifications of the BA scaffold led to the discovery of potent selective or dual FXR and GPBAR1 agonists. Herein, we discovered 7-ethylidene-lithocholic acid (7-ELCA) as a novel combined FXR antagonist/GPBAR1 agonist (IC50 = 15 μM/EC50 = 26 nM) with no off-target activation in a library of 7-alkyl substituted derivatives of BAs. 7-ELCA significantly suppressed the effect of the FXR agonist obeticholic acid in BSEP and SHP regulation in human hepatocytes. Importantly, 7-ELCA significantly stimulated the production of glucagon-like peptide-1 (GLP-1), an incretin with insulinotropic effect in postprandial glucose utilization, in intestinal enteroendocrine cells. We can suggest that 7-ELCA may be a prospective approach to the treatment of type II diabetes as the dual modulation of GPBAR1 and FXR has been supposed to be effective in the synergistic regulation of glucose homeostasis in the intestine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024161
003      
CZ-PrNML
005      
20211013134033.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2021.713149 $2 doi
035    __
$a (PubMed)34483922
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Stefela, Alzbeta $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
245    10
$a (E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells / $c A. Stefela, M. Kaspar, M. Drastik, T. Kronenberger, S. Micuda, M. Dracinsky, B. Klepetarova, E. Kudova, P. Pavek
520    9_
$a Bile acids (BAs) are key signaling steroidal molecules that regulate glucose, lipid, and energy homeostasis via interactions with the farnesoid X receptor (FXR) and G-protein bile acid receptor 1 (GPBAR1). Extensive medicinal chemistry modifications of the BA scaffold led to the discovery of potent selective or dual FXR and GPBAR1 agonists. Herein, we discovered 7-ethylidene-lithocholic acid (7-ELCA) as a novel combined FXR antagonist/GPBAR1 agonist (IC50 = 15 μM/EC50 = 26 nM) with no off-target activation in a library of 7-alkyl substituted derivatives of BAs. 7-ELCA significantly suppressed the effect of the FXR agonist obeticholic acid in BSEP and SHP regulation in human hepatocytes. Importantly, 7-ELCA significantly stimulated the production of glucagon-like peptide-1 (GLP-1), an incretin with insulinotropic effect in postprandial glucose utilization, in intestinal enteroendocrine cells. We can suggest that 7-ELCA may be a prospective approach to the treatment of type II diabetes as the dual modulation of GPBAR1 and FXR has been supposed to be effective in the synergistic regulation of glucose homeostasis in the intestine.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kaspar, Miroslav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czechia $u Faculty of Sciences, Charles University, Prague, Czechia
700    1_
$a Drastik, Martin $u Department of Physical Chemistry and Biophysics, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Kronenberger, Thales $u Department of Internal Medicine VIII, University Hospital of Tübingen, Tübingen, Germany $u School of Pharmacy, University of Eastern Finland, Faculty of Health Sciences, Kuopio, Finland
700    1_
$a Micuda, Stanislav $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Dracinsky, Martin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Klepetarova, Blanka $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Kudova, Eva $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Pavek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 12, č. - (2021), s. 713149
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34483922 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013134030 $b ABA008
999    __
$a ind $b bmc $g 1708210 $s 1144658
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 12 $c - $d 713149 $e 20210813 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Možnosti archivace